Skip Navigation

European Heart Journal 2004 25(9):720-722; doi:10.1016/j.ehj.2004.03.006
Copyright © 2004 by the European Society of Cardiology.
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (23)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Eriksson, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Eriksson, P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Current Opinion

Long-term clopidogrel therapy after percutaneous coronary intervention in PCI-CURE and CREDO: the "Emperor's New Clothes" revisited

Peter Eriksson*

Interventional Cardiology Laboratory, Department of Cardiology, Heart Centre, University Hospital, S-901 85 Umeå, Sweden

* Correspondence to: Tel.: +46-0-907856924/25; fax: +46-0-90137633
E-mail address: peter.eriksson@medicin.umu.se

The first 10% of the full text of this article appears below.

The Clopidogrel in Unstable angina to prevent Recurrent Events (PCI-CURE) trial1 showed that pretreatment with clopidogrel (300 mg loading dose, followed by 75 mg daily) in addition to aspirin for a median of 10 days before percutaneous coronary intervention (PCI), compared with aspirin alone, reduced the composite of cardiovascular death, myocardial infarction or urgent target vessel revascularisation by 30% (absolute risk reduction 1.9%, ) after 1 month. Long-term clopidogrel therapy, after 1 month of open-label ticlopidine or clopidogrel in stented patients in both groups, reduced the composite of death, myocardial infarction or any revascularisation by 16% (absolute risk reduction 3.4%, ) at the end of follow-up (mean 8 months). The . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Med Decis MakingHome page
L. Goldman and J.-M. Gaspoz
Cost-Effectiveness of Clopidogrel: Seeing through the Smoke
Med Decis Making, November 1, 2008; 28(6): 803 - 809.
[Abstract] [PDF]

Home page
 CirculationHome page
J. Daemen and P. W. Serruys
Drug-Eluting Stent Update 2007: Part II: Unsettled Issues
Circulation, August 21, 2007; 116(8): 961 - 968.
[Full Text] [PDF]

Home page
 CMAJHome page
E. L. Falcone and N. Tangri
Drug-eluting stents
Can. Med. Assoc. J., May 22, 2007; 176(11): 1611 - 1611.
[Full Text] [PDF]

Home page
 Circ. Res.Home page
T. A. Meadows and D. L. Bhatt
Clinical Aspects of Platelet Inhibitors and Thrombus Formation
Circ. Res., May 11, 2007; 100(9): 1261 - 1275.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
E. L. Falcone and N. Tangri
Clopidogrel and Long-term Outcomes After Drug-Eluting Stent Implantation
JAMA, April 25, 2007; 297(16): 1770 - 1770.
[Full Text] [PDF]

Home page
 Eur Heart JHome page
J. Daemen, H. M. Garcia-Garcia, N. Kukreja, F. Imani, P. P.T. de Jaegere, G. Sianos, R. T. van Domburg, and P. W. Serruys
The long-term value of sirolimus- and paclitaxel-eluting stents over bare metal stents in patients with diabetes mellitus
Eur. Heart J., January 1, 2007; 28(1): 26 - 32.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
G. Y. H. Lip and M. Karpha
Anticoagulant and Antiplatelet Therapy Use in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: The Need for Consensus and a Management Guideline
Chest, December 1, 2006; 130(6): 1823 - 1827.
[Abstract] [Full Text] [PDF]

Home page
 Mayo Clin Proc.Home page
G. W. Stone and H. D. Aronow
Long-term Care After Percutaneous Coronary Intervention: Focus on the Role of Antiplatelet Therapy
Mayo Clin. Proc., May 1, 2006; 81(5): 641 - 652.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
P. Eriksson
Economic Effects of Extended Clopidogrel Therapy--A Word of Caution
J. Am. Coll. Cardiol., October 4, 2005; 46(7): 1376 - 1376.
[Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
A. T.L. Ong, E. P. McFadden, E. Regar, P. P.T. de Jaegere, R. T. van Domburg, and P. W. Serruys
Late Angiographic Stent Thrombosis (LAST) Events With Drug-Eluting Stents
J. Am. Coll. Cardiol., June 21, 2005; 45(12): 2088 - 2092.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
P. A. Cowper, K. Udayakumar, M. H. Sketch Jr, and E. D. Peterson
Economic effects of prolonged clopidogrel therapy after percutaneous coronary intervention
J. Am. Coll. Cardiol., February 1, 2005; 45(3): 369 - 376.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
S. R. Steinhubl and E. J. Topol
Risk reduction with long-term clopidogrel following percutaneous coronary intervention
Eur. Heart J., December 1, 2004; 25(23): 2169 - 2170.
[Full Text] [PDF]

Home page
 Eur Heart JHome page
P. Eriksson
Reply: Long-term clopidogrel following PCI: marginal antithrombotic effects are offset by increased bleeding risks
Eur. Heart J., December 1, 2004; 25(23): 2170 - 2171.
[Full Text] [PDF]

Home page
 Eur Heart JHome page
T.W Koh
Long-term clopidogrel therapy in the drug-eluting stent era: beyond CREDO and PCI-CURE
Eur. Heart J., August 1, 2004; 25(15): 1364 - 1364.
[Full Text] [PDF]

Home page
 Eur Heart JHome page
P. Eriksson
Long-term clopidogrel therapy in the drug eluting stent era: beyond CREDO and CURE-PCI: Reply
Eur. Heart J., August 1, 2004; 25(15): 1364 - 1365.
[Full Text] [PDF]